AGL 8.30 Increased By ▲ 0.44 (5.6%)
ANL 10.59 Increased By ▲ 0.24 (2.32%)
AVN 78.60 Increased By ▲ 0.70 (0.9%)
BOP 5.45 Increased By ▲ 0.06 (1.11%)
CNERGY 5.59 Increased By ▲ 0.58 (11.58%)
EFERT 80.25 Decreased By ▼ -0.55 (-0.68%)
EPCL 69.60 Increased By ▲ 1.50 (2.2%)
FCCL 15.30 Increased By ▲ 0.74 (5.08%)
FFL 6.53 Increased By ▲ 0.33 (5.32%)
FLYNG 7.18 Increased By ▲ 0.53 (7.97%)
GGGL 10.85 Increased By ▲ 0.27 (2.55%)
GGL 16.79 Increased By ▲ 0.38 (2.32%)
GTECH 8.14 Increased By ▲ 0.02 (0.25%)
HUMNL 7.04 Increased By ▲ 0.02 (0.28%)
KEL 2.99 Increased By ▲ 0.11 (3.82%)
LOTCHEM 30.77 Increased By ▲ 2.24 (7.85%)
MLCF 28.98 Increased By ▲ 2.03 (7.53%)
OGDC 82.75 Increased By ▲ 0.60 (0.73%)
PAEL 16.97 Increased By ▲ 0.32 (1.92%)
PIBTL 6.08 Increased By ▲ 0.24 (4.11%)
PRL 18.10 Increased By ▲ 1.35 (8.06%)
SILK 1.15 Increased By ▲ 0.05 (4.55%)
TELE 11.25 Increased By ▲ 0.28 (2.55%)
TPL 9.20 Decreased By ▼ -0.02 (-0.22%)
TPLP 19.88 Increased By ▲ 0.22 (1.12%)
TREET 26.46 Increased By ▲ 0.55 (2.12%)
TRG 94.60 Increased By ▲ 0.99 (1.06%)
UNITY 19.50 Increased By ▲ 0.50 (2.63%)
WAVES 14.34 Increased By ▲ 0.78 (5.75%)
WTL 1.30 Increased By ▲ 0.06 (4.84%)
BR100 4,187 Increased By 80.1 (1.95%)
BR30 15,474 Increased By 343.5 (2.27%)
KSE100 42,096 Increased By 670.9 (1.62%)
KSE30 15,883 Increased By 222.7 (1.42%)
World

US plant ruins 15mn J&J coronavirus vaccine doses: report

  • The J&J vaccine has won praise for its single dosage and because it does not need to be frozen -- unlike the shots from Moderna and Pfizer -- making distribution much simpler.
Published April 1, 2021

WASHINGTON: About 15 million doses of the single-shot coronavirus vaccine made by Johnson & Johnson were ruined in a factory error in the United States, The New York Times reported -- a blow to the company's efforts to quickly boost production.

When contacted by AFP, the pharmaceutical giant said it had identified a batch of doses at a plant in Baltimore run by Emergent BioSolutions "that did not meet quality standards" but did not confirm the specific number affected.

The company also said the batch "was never advanced to the filling and finishing stages of our manufacturing process."

"Quality and safety continue to be our top priority," it said.

The Times report however signaled that issues with quality control could affect future output, with the Food and Drug Administration expected to investigate.

The FDA told AFP it was "aware of the situation" but declined to comment further.

Johnson & Johnson said it was sending more experts to the site to "supervise, direct and support all manufacturing of the Johnson & Johnson COVID-19 vaccine," which would allow it to deliver an additional 24 million shots "through April."

The Emergent BioSolutions plant had not yet been authorized by US regulators to manufacture a "drug substance" for the J&J vaccine, the company said, but US media reported that it was expected to produce tens of millions of doses in the near future.

The J&J vaccine has won praise for its single dosage and because it does not need to be frozen -- unlike the shots from Moderna and Pfizer -- making distribution much simpler.

"We continue to expect to deliver our Covid-19 vaccine at a rate of more than one billion doses by the end of 2021," J&J said.

Comments

Comments are closed.